which glp-1 agonists have cardiovascular benefit and mortality outcomes with receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia GLP-1 receptor agonists: The cardiovascular

Description

Imaging 3 , 195201 (2010)

Foundayo Foundayo is made by Eli Lilly, the same manufacturer behind the injectable GLP-1 medications Mounjaro and Zepbound

or analogs of human GLP-1, with changes in the amino acid sequence that make them resistant to dipeptidylpeptidase 4

While most of the cancer-preventing benefits seem to come from the drugs reducing obesity a risk factor for over a dozen forms of cancer the findings also suggested that the drugs have anti-inflammatory effects that can stymy cancer development and even suppress tumors

These interactions highlight the complex and integrated role of gut-derived peptides in modulating cardiovascular function, emphasizing the therapeutic potential of targeting these pathways in cardiovascular diseases as captured below under gaps and new areas of investigation